["lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated: ovarian cancer \u2022 for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.1, 2.1) \u2022 in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either: \u2022 a deleterious or suspected deleterious brca mutation, and/or \u2022 genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.2, 2.1) \u2022 for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.3, 2.1) breast cancer \u2022 for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.4, 2.1) \u2022 for the treatment of adult patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.5, 2.1) pancreatic cancer \u2022 for the maintenance treatment of adult patients with deleterious or suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.6, 2.1) prostate cancer \u2022 for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.7, 2.1) \u2022 in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.8, 2.1)", "yervoy is a human cytotoxic t-lymphocyte antigen 4 (ctla-4)-blocking antibody indicated for: melanoma \u2022 treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) \u2022 adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) renal cell carcinoma (rcc) \u2022 treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) colorectal cancer \u2022 treatment of adults and pediatric patients 12 years and older patients with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) colorectal cancer (crc) in combination with nivolumab. (1.4) hepatocellular carcinoma \u2022 adult patients with unresectable or metastatic hepatocellular carcinoma (hcc) as first-line treatment in combination with nivolumab. (1.5) \u2022 in combination with nivolumab in adult patients with unresectable or metastatic hcc who have been previously treated with sorafenib. (1.5) non-small cell lung cancer (nsclc) \u2022 treatment of adult patients with metastatic non-small cell lung cancer expressing pd-l1 (\u22651%) as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) \u2022 treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) malignant pleural mesothelioma \u2022 treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) esophageal cancer \u2022 treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab. (1.8)", "lorbrena is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test. (1, 2.1)", "vitrakvi is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:  have a neurotrophic receptor tyrosine kinase (ntrk) gene fusion without a known acquired resistance mutation,  are metastatic or where surgical resection is likely to result in severe morbidity, and  have no satisfactory alternative treatments or that have progressed following treatment. select patients for therapy based on an fda-approved test. (1, 2.1)", "ojemda is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low- grade glioma (lgg) harboring a braf fusion or rearrangement, or braf v600 mutation. (1) this indication is approved under accelerated approval based on response rate and duration of response [see clinical studies (14)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).", "sprycel is a kinase inhibitor indicated for the treatment of  newly diagnosed adults with philadelphia chromosome-positive (ph+) chronic myeloid leukemia (cml) in chronic phase. (1, 14)  adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib. (1, 14)  adults with philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all) with resistance or intolerance to prior therapy. (1, 14)  pediatric patients 1 year of age and older with ph+ cml in chronic phase. (1, 14)  pediatric patients 1 year of age and older with newly diagnosed ph+ all in combination with chemotherapy. (1, 14)", "margenza is a her2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic her2- positive breast cancer who have received two or more prior anti-her2 regimens, at least one of which was for metastatic disease. (1, 2.1, 14.1)", "iressa is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test. (1) limitation of use: safety and efficacy of iressa have not been established in patients whose tumors have egfr mutations other than exon 19 deletions or exon 21 (l858r) substitution mutations. (1)", "kadcyla is a her2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: \u2022 the treatment of patients with her2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either: \u2022 received prior therapy for metastatic disease, or \u2022 developed disease recurrence during or within six months of completing adjuvant therapy. (1.1) \u2022 the adjuvant treatment of patients with her2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. (1.2) select patients for therapy based on an fda-approved companion diagnostic for kadcyla [see dosage and administration (2.1)] ", "zykadia is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test. (1, 2.1)", "vectibix is an epidermal growth factor receptor (egfr) antagonist indicated for the treatment of wild-type ras (defined as wild-type in both kras and nras as determined by an fda-approved test for this use) metastatic colorectal cancer (mcrc): \u2022 in combination with folfox for first-line treatment. (1.1, 14.2) \u2022 as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. (1.1, 14.1) \u2022 limitation of use: vectibix is not indicated for the treatment of patients with ras-mutant mcrc or for whom ras mutation status is unknown. (1.1, 2.1, 5.2, 12.1)", "mylotarg is a cd33-directed antibody and cytotoxic drug conjugate indicated for: \u2022 treatment of newly-diagnosed cd33-positive acute myeloid leukemia (aml) in adults and pediatric patients 1 month and older (1.1). \u2022 treatment of relapsed or refractory cd33-positive aml in adults and pediatric patients 2 years and older (1.2).", "pemazyre is a kinase inhibitor indicated: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test. (1,2.1) this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1,2.1) for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (mlns) with fgfr1 rearrangement. (1,2.1)", "rybrevant is a bispecific egf receptor-directed and met receptor- directed antibody indicated: \u2022 in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r substitution mutations, as detected by an fda-approved test. (1, 2.2) \u2022 in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 19 deletions or exon 21 l858r substitution mutations, whose disease has progressed on or after treatment with an egfr tyrosine kinase inhibitor. (1, 2.2) \u2022 in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 20 insertion mutations, as detected by an fda-approved test. (1, 2.2) \u2022 as a single agent for the treatment of adult patients with locally advanced or metastatic nsclc with egfr exon 20 insertion mutations, as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemotherapy. (1, 2.2)", "idhifa is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation as detected by an fda- approved test (1.1).", "mekinist is a kinase inhibitor indicated as a single agent for the treatment of braf-inhibitor treatment-nai\u0308ve patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda- approved test. (1.1, 2.1) mekinist is indicated, in combination with dabrafenib, for: \u2022 the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. (1.1, 2.1) \u2022 the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection. (1.2, 2.1) \u2022 the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test. (1.3, 2.1) \u2022 the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options. (1.4, 2.1) \u2022 the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1.5, 2.1) \u2022 the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy. (1.6, 2.1) limitations of use: mekinist is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibition. (1.7, 12.1)", "xospata is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation as detected by an fda-approved test. (1.1)", "retevmo\u00ae is a kinase inhibitor indicated for the treatment of: \u2022 adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with a rearranged during transfection (ret) gene fusion, as detected by an fda-approved test (1.1) \u2022 adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (mtc) with a ret mutation, as detected by an fda-approved test, who require systemic therapy (1.2) \u2022 adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a ret gene fusion, as detected by an fda-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) (1.3) \u2022 adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a ret gene fusion, as detected by an fda-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options1 (1.4) this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).", "zejula is a poly (adp-ribose) polymerase (parp) inhibitor indicated: with antihypertensive medications and adjustment of the dose of \u2022 for the maintenance treatment of adult patients with advanced epithelial zejula, if necessary. (5.3) ovarian, fallopian tube, or primary peritoneal cancer who are in a \u2022 posterior reversible encephalopathy syndrome (pres): pres has complete or partial response to first-line platinum-based chemotherapy. occurred in patients treated with zejula. discontinue zejula if pres (1.1) is confirmed. (5.4) \u2022 for the maintenance treatment of adult patients with deleterious or \u2022 embryo-fetal toxicity: zejula can cause fetal harm. advise females of suspected deleterious germline brca-mutated recurrent epithelial reproductive potential of the potential risk to a fetus and to use effective ovarian, fallopian tube, or primary peritoneal cancer who are in a contraception. (5.5, 8.1, 8.3) complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for ------------------------------- adverse reactions ------------------------------ zejula (1.2, 2.1) most common adverse reactions (incidence \u226510%) in patients who received zejula were nausea, thrombocytopenia, anemia, fatigue, constipation,", "ibtrozi is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc). (1)", "\u2022 zelboraf\u00ae is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test. (1.1, 2.1) \u2022 zelboraf\u00ae is indicated for the treatment of patients with erdheim- chester disease with braf v600 mutation. (1.2, 2.1) limitation of use: zelboraf is not indicated for treatment of patients with wild-type braf melanoma (2.1, 5.2)", "avmapki fakzynja co-pack, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with kras-mutated recurrent low-grade serous ovarian cancer (lgsoc) who have received prior systemic therapy. this indication is approved under accelerated approval based on tumor response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. (1,14)", "afinitor is a kinase inhibitor indicated for the treatment of: \u2022 postmenopausal women with advanced hormone receptor-positive, her2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) \u2022 adults with progressive neuroendocrine tumors of pancreatic origin (pnet) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (net) of gastrointestinal (gi) or lung origin that are unresectable, locally advanced or metastatic. limitations of use: afinitor is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) \u2022 adults with advanced renal cell carcinoma (rcc) after failure of treatment with sunitinib or sorafenib. (1.3) \u2022 adults with renal angiomyolipoma and tuberous sclerosis complex (tsc), not requiring immediate surgery. (1.4) afinitor and afinitor disperz are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with tsc who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected. (1.5) afinitor disperz is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tsc- associated partial-onset seizures. (1.6)", "faslodex is an estrogen receptor antagonist indicated for the treatment of: \u2022 hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) \u2022 hr-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) \u2022 hr-positive, her2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) \u2022 hr-positive, her2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)", "datroway is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:  adult patients with locally advanced or metastatic epidermal growth factor receptor (egfr)-mutated non-small cell lung cancer (nsclc) who have received prior egfr-directed therapy and platinum-based chemotherapy. (1.1) this indication is approved under accelerated approval based on objective response rate and duration of response [see clinical studies (14.1)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.  adult patients with unresectable or metastatic, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)- negative (ihc 0, ihc 1+ or ihc 2+/ish-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. (1.2)", "tukysa is a kinase inhibitor indicated: \u2022 in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic her2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-her2-based regimens in the metastatic setting. (1.1) \u2022 in combination with trastuzumab for the treatment of adult patients with ras wild-type her2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (1.2) this indication is approved under accelerated approval based on tumor response rate and durability of response [see clinical studies (14.2)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.", "revlimid is a thalidomide analogue indicated for the treatment of adult patients with:  multiple myeloma (mm), in combination with dexamethasone (1.1).  mm, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct) (1.1).  transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2).  mantle cell lymphoma (mcl) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3).  previously treated follicular lymphoma (fl), in combination with a rituximab product  (1.4).  previously treated marginal zone lymphoma (mzl), in combination with a rituximab product (1.5). limitations of use:  revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (cll) outside of controlled clinical trials (1.4).", "ziihera is indicated for the treatment of adults with previously treated, unresectable or metastatic her2-positive (ihc 3+) biliary tract cancer (btc), as detected by an fda-approved test [see dosage and administration (2.1)]. this indication is approved under accelerated approval based on overall response rate and duration of response [see clinical studies (14)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 2", "tagrisso is a kinase inhibitor indicated for:  adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. (1.1, 2.2)  the treatment of adult patients with locally advanced, unresectable (stage iii) nsclc whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. (1.2, 2.2)  the first-line treatment of adult patients with metastatic nsclc whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. (1.3, 2.2)  in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic nsclc whose tumors have egfr exon 19 deletions or exon 21 l858r mutations, as detected by an fda-approved test. (1.4, 2.2)  the treatment of adult patients with metastatic egfr t790m mutation- positive nsclc, as detected by an fda-approved test, whose disease has progressed on or after egfr tki therapy. (1.5, 2.2)", "blincyto is a bispecific cd19-directed cd3 t-cell engager indicated for the treatment of adult and pediatric patients one month and older with: \u2022 cd19-positive b-cell precursor acute lymphoblastic leukemia (all) in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%. (1.1) \u2022 relapsed or refractory cd19-positive b-cell precursor acute lymphoblastic leukemia (all). (1.2) \u2022 cd19-positive philadelphia chromosome-negative b-cell precursor acute lymphoblastic leukemia (all) in the consolidation phase of multiphase chemotherapy. (1.3)", "emrelis is a c-met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsclc) with high c-met protein overexpression [\u226550% of tumor cells with strong (3+) staining], as determined by an fda-approved test, who have received a prior systemic therapy. (1) this indication is approved under accelerated approval based on overall response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1)", "scemblix is a kinase inhibitor indicated for the treatment of adult patients with: \u2022 newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp). this indication is approved under accelerated approval based on major molecular response rate. continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). (1) \u2022 previously treated ph+ cml in cp. (1) \u2022 ph+ cml in cp with the t315i mutation. (1)", "gleevec is a kinase inhibitor indicated for the treatment of: \u2022 newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. (1.1) \u2022 patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in blast crisis (bc), accelerated phase (ap), or in chronic phase (cp) after failure of interferon-alpha therapy. (1.2) \u2022 adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all). (1.3) \u2022 pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) in combination with chemotherapy. (1.4) \u2022 adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. (1.5) \u2022 adult patients with aggressive systemic mastocytosis (asm) without the d816v c-kit mutation or with c-kit mutational status unknown. (1.6) \u2022 adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukemia (cel) who have the fip1l1-pdgfr\u03b1 fusion kinase (mutational analysis or fluorescence in situ hybridization [fish] demonstration of chic2 allele deletion) and for patients with hes and/or cel who are fip1l1-pdgfr\u03b1 fusion kinase negative or unknown. (1.7) \u2022 adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). (1.8) \u2022 patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist). (1.9) \u2022 adjuvant treatment of adult patients following resection of kit (cd117) positive gist. (1.10)", "alecensa is a kinase inhibitor indicated for: \u2022 adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) (tumors \u2265 4 cm or node positive) as detected by an fda- approved test. (1.1) \u2022 treatment of adult patients with alk-positive metastatic nsclc as detected by an fda-approved test. (1.2)", "vyloy is a claudin 18.2-directed cytolytic antibody and is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (her2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (cldn) 18.2 positive as determined by an fda-approved test (1).", "lumakras is an inhibitor of the ras gtpase family indicated for the treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy. (1) this indication is approved under accelerated approval based on overall response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1)", "tabrecta is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an fda-approved test. (1)", "exkivity is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutations, as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemotherapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). (1, 2.2)", "vizimpro is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 19 deletion or exon 21 l858r substitution mutations as detected by an fda-approved test. (1)", "talzenna is a poly (adp-ribose) polymerase (parp) inhibitor indicated for: breast cancer \u2022 as a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline brca-mutated (gbrcam) her2-negative locally advanced or metastatic breast cancer. select patients for therapy based on an fda-approved companion diagnostic for talzenna. (1.1) hrr gene-mutated mcrpc \u2022 in combination with enzalutamide for the treatment of adult patients with hrr gene-mutated metastatic castration-resistant prostate cancer (mcrpc). (1.2)", "iclusig is a kinase inhibitor indicated for the treatment of adult patients with: philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all) \u2022 newly diagnosed ph+ all, in combination with chemotherapy. (1) this indication is approved under accelerated approval based on minimal residual disease (mrd)-negative complete remission (cr) at the end of induction. continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). \u2022 as monotherapy in ph+ all for whom no other kinase inhibitors are indicated or t315i-positive ph+ all. (1) chronic myeloid leukemia (cml) \u2022 chronic phase (cp) cml with resistance or intolerance to at least two prior kinase inhibitors. (1) \u2022 accelerated phase (ap) or blast phase (bp) cml for whom no other kinase inhibitors are indicated. (1) \u2022 t315i-positive cml (chronic phase, accelerated phase, or blast phase). (1) limitations of use: iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed cp-cml. (5.7)", "jemperli is a programmed death receptor-1 (pd-1)\u2013blocking antibody thyroid function, at baseline and periodically during treatment. withhold indicated: or permanently discontinue jemperli and administer corticosteroids endometrial cancer (ec) based on the severity of reaction. (2.3, 5.1) \u2022 in combination with carboplatin and paclitaxel, followed by jemperli \u2022 infusion-related reactions: interrupt, slow the rate of infusion, or as a single agent for the treatment of adult patients with primary advanced permanently discontinue jemperli based on severity of reaction. (2.3, or recurrent endometrial cancer that is mismatch repair deficient 5.2) (dmmr), as determined by an fda-approved test, or microsatellite \u2022 complications of allogeneic hematopoietic stem cell transplantation instability-high (msi-h). (1.1, 2.1) (hsct): fatal and other serious complications can occur in patients who \u2022 as a single agent for the treatment of adult patients with dmmr recurrent receive allogeneic hsct before or after being treated with a or advanced endometrial cancer, as determined by an fda-approved test, pd-1/pd-l1\u2013blocking antibody. (5.3) that has progressed on or following prior treatment with a platinum- \u2022 embryo-fetal toxicity: can cause fetal harm. advise females of containing regimen in any setting and are not candidates for curative reproductive potential of the potential risk to a fetus and to use effective surgery or radiation. (1.1, 2.1) contraception. (5.4, 8.1, 8.3) mismatch repair deficient recurrent or advanced solid tumors \u2022 as a single agent for the treatment of adult patients with dmmr recurrent ------------------------------- adverse reactions ------------------------------ or advanced solid tumors, as determined by an fda-approved test, that \u2022 most common adverse reactions (\u226520%) with jemperli in combination have progressed on or following prior treatment and who have no with carboplatin and paclitaxel in patients with dmmr/msi-h ec are satisfactory alternative treatment options.1 (1, 2.1) rash, diarrhea, hypothyroidism, and hypertension. most common grade 3 1this indication is approved under accelerated approval based on tumor or 4 laboratory abnormalities (\u226510%) are decreased neutrophils, decreased response rate and durability of response. continued approval for this hemoglobin, decreased white blood cell count, decreased lymphocytes, indication may be contingent upon verification and description of clinical increased glucose, decreased sodium, and decreased platelets. (6.1) benefit in a confirmatory trial(s). (1) \u2022 most common adverse reactions (\u226520%) with jemperli as a single agent in patients with dmmr solid tumors are fatigue/asthenia, anemia, ------------------------", "phesgo is a combination of pertuzumab and trastuzumab, her2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: \u2022 use in combination with chemotherapy as: o neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (1.1) o adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence (1.1) \u2022 use in combination with docetaxel for treatment of patients with her2 positive metastatic breast cancer (mbc) who have not received prior anti-her2 therapy or chemotherapy for metastatic disease. (1.2) ", "tarceva is a kinase inhibitor indicated for: \u2022 the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. (1.1) \u2022 first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. (1.2) limitations of use: \u2022 safety and efficacy of tarceva have not been established in patients with nsclc whose tumors have other egfr mutations. (1.1) \u2022 tarceva is not recommended for use in combination with platinum- based chemotherapy. (1.1)", "akeega is a combination of niraparib, a poly (adp-ribose) polymerase (parp) inhibitor, and abiraterone acetate, a cyp17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved test for akeega. (1, 2.1)", "tibsovo is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for patients with a susceptible idh1 mutation as detected by an fda-approved test with: newly diagnosed acute myeloid leukemia (aml) \u2022 in combination with azacitidine or as monotherapy for the treatment of newly diagnosed aml in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy (1.1). relapsed or refractory aml \u2022 for the treatment of adult patients with relapsed or refractory aml (1.2). relapsed or refractory myelodysplastic syndromes (mds) \u2022 for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (1.3). locally advanced or metastatic cholangiocarcinoma \u2022 for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated (1.4).", "rydapt is a kinase inhibitor indicated for the treatment of adult patients with: \u2022 newly diagnosed acute myeloid leukemia (aml) that is flt3 mutation- positive as detected by an fda-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. (1.1) limitations of use: rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. \u2022 aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl). (1.2)", "zegfrovy is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion mutations, as detected by an fda-approved test, whose disease has progressed on or after platinum-based chemotherapy. (1, 2.1) this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). (1)", "trisenox is an arsenical indicated: \u2022 in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (apl) whose apl is characterized by the presence of the t(15;17) translocation or pml/rar-alpha gene expression. (1.1) \u2022 for induction of remission and consolidation in patients with apl who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterized by the presence of the t(15;17) translocation or pml/rar-alpha gene expression. (1.2)", "cyramza\u00ae is a human vascular endothelial growth factor receptor 2 (vegfr2) antagonist indicated: \u2022 as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. (1.1) \u2022 in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) mutations. (1.2) \u2022 in combination with docetaxel, for treatment of metastatic non- small cell lung cancer with disease progression on or after platinum-based chemotherapy. patients with egfr or alk genomic tumor aberrations should have disease progression on fda-approved therapy for these aberrations prior to receiving cyramza. (1.2) \u2022 in combination with folfiri, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (1.3) \u2022 as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of \u2265400 ng/ml and have been treated with sorafenib. (1.4)", "rubraca is a poly (adp-ribose) polymerase (parp) inhibitor indicated: ovarian cancer \u2022 for the maintenance treatment of adult patients with a deleterious brca mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. (1.1) prostate cancer \u2022 for the treatment of adult patients with a deleterious brca mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for rubraca. (1.2, 2.1) this indication is approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1.2)", "xeloda (capecitabine) is a nucleoside metabolic inhibitor indicated for: colorectal cancer \u2022 adjuvant treatment of patients with stage iii colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) \u2022 perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) \u2022 treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) breast cancer \u2022 treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. (1.2) \u2022 treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) gastric, esophageal, or gastroesophageal junction cancer \u2022 treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) \u25cf treatment of adults with her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) pancreatic cancer \u2022 adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4)", "krazati is an inhibitor of the ras gtpase family indicated for the treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior systemic therapy. (1) this indication is approved under accelerated approval based on objective response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s). (1) _______________", "trodelvy is a trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: locally advanced or metastatic breast cancer \u2022 unresectable locally advanced or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, at least one of them for metastatic disease. (1.1, 14.1) \u2022 unresectable locally advanced or metastatic hormone receptor (hr)- positive, human epidermal growth factor receptor 2 (her2)-negative (ihc 0, ihc 1+ or ihc 2+/ish\u2013) breast cancer who have received endocrine- based therapy and at least two additional systemic therapies in the metastatic setting. (1.1, 14.2) locally advanced or metastatic urothelial cancer \u2022 locally advanced or metastatic urothelial cancer (muc) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (pd-1) or programmed death-ligand 1 (pd- l1) inhibitor.a (1.2) a this indication is approved under accelerated approval based on tumor response rate and duration of response [see clinical studies (14.3)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.", "rituxan is a cd20-directed cytolytic antibody indicated for the treatment of: \u2022 adult patients with non-hodgkin\u2019s lymphoma (nhl) (1.1). o relapsed or refractory, low grade or follicular, cd20-positive b- cell nhl as a single agent. o previously untreated follicular, cd20-positive, b-cell nhl in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. o non-progressing (including stable disease), low-grade, cd20 positive, b-cell nhl as a single agent after first-line cyclophosphamide, vincristine, and prednisone (cvp) chemotherapy. o previously untreated diffuse large b-cell, cd20-positive nhl in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (chop) or other anthracycline-based chemotherapy regimens. \u2022 pediatric patients aged 6 months and older with mature b-cell nhl and mature b-cell acute leukemia (b-al) (1.1) o previously untreated, advanced stage, cd20-positive, diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymphoma (bll) or mature b-cell acute leukemia (b-al) in combination with chemotherapy. \u2022 adult patients with chronic lymphocytic leukemia (cll) (1.2). o previously untreated and previously treated cd20-positive cll in combination with fludarabine and cyclophosphamide (fc). \u2022 rheumatoid arthritis (ra) in combination with methotrexate in adult patients with moderately-to severely-active ra who have inadequate response to one or more tnf antagonist therapies (1.3). \u2022 granulomatosis with polyangiitis (gpa) (wegener\u2019s granulomatosis) and microscopic polyangiitis (mpa) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids (1.4). \u2022 moderate to severe pemphigus vulgaris (pv) in adult patients (1.5).", "ayvakit is a kinase inhibitor indicated for: gastrointestinal stromal tumor (gist) \u2022 the treatment of adults with unresectable or metastatic gist harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation, including pdgfra d842v mutations. (1.1, 2.2) advanced systemic mastocytosis (advsm) \u2022 the treatment of adult patients with advsm. advsm includes patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm- ahn), and mast cell leukemia (mcl). (1.2) \u2022 limitations of use: ayvakit is not recommended for the treatment of patients with advsm with platelet counts of less than 50 x 109/l (1.2) indolent systemic mastocytosis (ism) \u2022 the treatment of adult patients with ism. (1.3) \u2022 limitations of use: ayvakit is not recommended for the treatment of patients with ism with platelet counts of less than 50 x 109/l (1.2)", "adcetris is a cd30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: \u2022 adult patients with previously untreated stage iii or iv classical hodgkin lymphoma (chl), in combination with doxorubicin, vinblastine, and dacarbazine (1.1). \u2022 pediatric patients 2 years and older with previously untreated high risk classical hodgkin lymphoma (chl), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (1.2). \u2022 adult patients with classical hodgkin lymphoma (chl) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-hsct) consolidation (1.3). \u2022 adult patients with classical hodgkin lymphoma (chl) after failure of auto-hsct or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-hsct candidates (1.4). \u2022 adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t- cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone (1.5). \u2022 adult patients with systemic anaplastic large cell lymphoma (salcl) after failure of at least one prior multi-agent chemotherapy regimen (1.6). \u2022 adult patients with primary cutaneous anaplastic large cell lymphoma (pcalcl) or cd30-expressing mycosis fungoides (mf) who have received prior systemic therapy (1.7).", "piqray is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3ca-mutated, advanced or metastatic breast cancer as detected by an fda-approved test following progression on or after an endocrine-based regimen. (1)", "keytruda is a programmed death receptor-1 (pd-1)-blocking antibody indicated: melanoma \u2022 for the treatment of patients with unresectable or metastatic melanoma. (1.1) \u2022 for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage iib, iic, or iii melanoma following complete resection. (1.1) non-small cell lung cancer (nsclc) \u2022 in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous nsclc, with no egfr or alk genomic tumor aberrations. (1.2) \u2022 in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous nsclc. (1.2) \u2022 as a single agent for the first-line treatment of patients with nsclc expressing pd-l1 [tumor proportion score (tps) \u22651%] as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, and is: o stage iii where patients are not candidates for surgical resection or definitive chemoradiation, or o metastatic. (1.2, 2.1) \u2022 as a single agent for the treatment of patients with metastatic nsclc whose tumors express pd-l1 (tps \u22651%) as determined by an fda-approved test, with disease progression on or after platinum-containing chemotherapy. patients with egfr or alk genomic tumor aberrations should have disease progression on fda-approved therapy for these aberrations prior to receiving keytruda. (1.2, 2.1) \u2022 for the treatment of patients with resectable (tumors \u22654 cm or node positive) nsclc in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. (1.2) \u2022 as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage ib (t2a \u22654 cm), ii, or iiia nsclc. (1.2) malignant pleural mesothelioma (mpm) \u2022 in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic mpm. (1.3) head and neck squamous cell cancer (hnscc) \u2022 for the treatment of adult patients with resectable locally advanced hnscc whose tumors express pd-l1 [combined positive score (cps) \u22651] as determined by an fda-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (rt) with or without cisplatin and then as a single agent. (1.4) \u2022 in combination with platinum and fu for the first-line treatment of patients with metastatic or with unresectable, recurrent hnscc. (1.4) \u2022 as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent hnscc whose tumors express pd-l1 [combined positive score (cps) \u22651] as determined by an fda-approved test. (1.4, 2.1) \u2022 as a single agent for the treatment of patients with recurrent or metastatic hnscc with disease progression on or after platinum-containing chemotherapy. (1.4) classical hodgkin lymphoma (chl) \u2022 for the treatment of adult patients with relapsed or refractory chl. (1.5) \u2022 for the treatment of pediatric patients with refractory chl, or chl that has relapsed after 2 or more lines of therapy. (1.5) primary mediastinal large b-cell lymphoma (pmbcl) \u2022 for the treatment of adult and pediatric patients with refractory pmbcl, or who have relapsed after 2 or more prior lines of therapy. (1.6) \u2022 limitations of use: keytruda is not recommended for treatment of patients with pmbcl who require urgent cytoreductive therapy. urothelial cancer \u2022 in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. (1.7) \u2022 as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: o are not eligible for any platinum-containing chemotherapy, or o who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum- containing chemotherapy. (1.7) \u2022 as a single agent for the treatment of patients with bacillus calmette-guerin (bcg)-unresponsive, high-risk, non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. (1.7) microsatellite instability-high or mismatch repair deficient cancer \u2022 for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) solid tumors, as determined by an fda-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (1.8, 2.1) microsatellite instability-high or mismatch repair deficient colorectal cancer (crc) \u2022 for the treatment of patients with unresectable or metastatic msi-h or dmmr colorectal cancer (crc) as determined by an fda-approved test. (1.9, 2.1) gastric cancer \u2022 in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps \u22651) as determined by an fda-approved test. (1.10) \u2022 in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic her2-negative gastric or gastroesophageal junction (gej) adenocarcinoma whose tumors express pd-l1 (cps \u22651) as determined by an fda- approved test. (1.10) esophageal cancer \u2022 for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (gej) (tumors with epicenter 1 to 5 centimeters above the gej) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: o in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express pd-l1 (cps \u22651), or o as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express pd-l1 (cps \u226510) as determined by an fda-approved test. (1.11, 2.1) cervical cancer \u2022 in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (figo 2014 stage iii-iva). (1.12) \u2022 in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express pd-l1 (cps \u22651) as determined by an fda-approved test. (1.12, 2.1) reference id: 5630536 \u2022 as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express pd-l1 (cps \u22651) as determined by an fda-approved test. (1.12, 2.1) hepatocellular carcinoma (hcc) \u2022 for the treatment of patients with hcc secondary to hepatitis b who have received prior systemic therapy other than a pd- 1/pd-l1-containing regimen. (1.13) biliary tract cancer (btc) \u2022 in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. (1.14) merkel cell carcinoma (mcc) \u2022 for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic merkel cell carcinoma. (1.15) renal cell carcinoma (rcc) \u2022 in combination with axitinib, for the first-line treatment of adult patients with advanced rcc. (1.16) \u2022 in combination with lenvatinib, for the first-line treatment of adult patients with advanced rcc. (1.16) \u2022 for the adjuvant treatment of patients with rcc at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. (1.16) endometrial carcinoma \u2022 in combination with carboplatin and paclitaxel, followed by keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. (1.17) \u2022 in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pmmr) or not msi-h as determined by an fda-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. (1.17, 2.1) \u2022 as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is msi-h or dmmr, as determined by an fda-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. (1.17, 2.1) tumor mutational burden-high (tmb-h) cancer \u2022 for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (tmb-h) [\u226510 mutations/megabase (mut/mb)] solid tumors, as determined by an fda-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.1 (1.18, 2.1) \u2022 limitations of use: the safety and effectiveness of keytruda in pediatric patients with tmb-h central nervous system cancers have not been established. cutaneous squamous cell carcinoma (cscc) \u2022 for the treatment of patients with recurrent or metastatic cscc or locally advanced cscc that is not curable by surgery or radiation. (1.19) triple-negative breast cancer (tnbc) \u2022 for the treatment of patients with high-risk early-stage tnbc in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. (1.20) \u2022 in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic tnbc whose tumors express pd-l1 (cps \u226510) as determined by an fda approved test. (1.20, 2.1) this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.", "elahere is a folate receptor alpha (fr\u03b1)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with fr\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. select patients for therapy based on an fda-approved test. (1, 2.1)", "voranigo is an isocitrate dehydrogenase-1 (idh1) and isocitrate dehydrogenase-2 (idh2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible idh1 or idh2 mutation following surgery including biopsy, sub-total resection, or gross total resection. (1)", "alunbrig is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test. (1, 2.1)", "besponsa is a cd22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory cd22-positive b-cell precursor acute lymphoblastic leukemia (all) in adult and pediatric patients 1 year and older. (1)", "tecentriq is a programmed death-ligand 1 (pd-l1) blocking antibody indicated: non-small cell lung cancer (nsclc) \u2022 as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage ii to iiia  nsclc whose tumors have pd-l1 expression on \u2265 1% of tumor cells, as determined by an fda-approved test. (1.1, 14.1) \u2022 for the first-line treatment of adult patients with metastatic nsclc whose tumors have high pd-l1 expression (pd-l1 stained \u2265 50% of tumor cells [tc \u2265 50%] or pd-l1 stained tumor-infiltrating immune cells [ic] covering \u2265 10% of the tumor area [ic \u2265 10%] ), as determined by an fda- approved test, with no egfr or alk genomic tumor aberrations. (1.1) \u2022   in combination with bevacizumab, paclitaxel, and carboplatin, for the first- line treatment of adult patients with metastatic non-squamous nsclc with no egfr or alk genomic tumor aberrations. (1.1) \u2022 in combination with paclitaxel protein-bound and carboplatin for the first- line treatment of adult patients with metastatic non-squamous nsclc with no egfr or alk genomic tumor aberrations (1.1) \u2022 for the treatment of adult patients with metastatic nsclc who have disease progression during or following platinum-containing chemotherapy. patients with egfr or alk genomic tumor aberrations should have disease progression on fda-approved therapy for nsclc harboring these aberrations prior to receiving tecentriq. (1.1) small cell lung cancer (sclc) \u2022   in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc). (1.2) hepatocellular carcinoma (hcc) \u2022 in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic hcc who have not received prior systemic therapy. (1.3) melanoma \u2022   in combination with cobimetinib and vemurafenib for the treatment of adult patients with braf v600 mutation-positive unresectable or metastatic melanoma. (1.4) alveolar soft part sarcoma (asps) \u2022 for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic asps. (1.5) ", "xalkori is a kinase inhibitor indicated for the treatment of \u2022 adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk) or ros1-positive as detected by an fda-approved test. (1.1, 2.1) \u2022 pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is alk-positive. (1.2, 2.2) o limitations of use: the safety and efficacy of xalkori have not been established in older adults with relapsed or refractory, systemic alk-positive alcl. \u2022 adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (imt) that is alk-positive. (1.3, 2.2)", "kisqali is a kinase inhibitor indicated: \u2022 in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative stage ii and iii early breast cancer at high risk of recurrence. (1) \u2022 for the treatment of adults with hr-positive, her2-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy; or o fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. (1)", "orserdu is an estrogen receptor antagonist indicated for: \u2022 treatment of postmenopausal women or adult men, with er- positive, her2-negative, esr1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy (1)", "nerlynx is a kinase inhibitor indicated: \u2022 as a single agent, for the extended adjuvant treatment of adult patients with early-stage her2-positive breast cancer, to follow adjuvant trastuzumab based therapy. (1.1) \u2022 in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting. (1.2) _______________", "revuforj is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older. (1).", "hernexeos is a kinase inhibitor indicated for the treatment of adult ------------------------------adverse reactions------------------------------- patients with unresectable or metastatic non-squamous non-small cell lung most common adverse reactions (\u2265 20%) are diarrhea, hepatotoxicity, rash, cancer (nsclc) whose tumors have her2 (erbb2) tyrosine kinase domain fatigue, and nausea. (6.1) activating mutations, as detected by an fda-approved test, and who have the most common (\u2265 2%) grade 3 or 4 laboratory abnormalities were received prior systemic therapy. (1) decreased lymphocytes, increased alanine aminotransferase, increased aspartate aminotransferase, decreased potassium, and increased gamma this indication is approved under accelerated approval based on objective glutamyl transferase. (6.1) response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a to report suspected adverse reactions, contact boehringer confirmatory trial. (1) ingelheim pharmaceuticals, inc. at 1-800-542-6257 or fda at 1-800-fda- 1088 or www.fda.gov/medwatch.", "cotellic\u00ae is a kinase inhibitor indicated: \u2022 for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, in combination with vemurafenib. (1.1, 14.1) \u2022 as a single agent for the treatment of adult patients with histiocytic neoplasms. (1.2, 14.2)", "tepmetko is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) harboring mesenchymal- epithelial transition (met) exon 14 skipping alterations. (1)", "imjudo is a cytotoxic t-lymphocyte-associated antigen 4 (ctla-4) blocking antibody indicated:  in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uhcc). (1.1)  in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with no sensitizing epidermal growth factor receptor (egfr) mutation or anaplastic lymphoma kinase (alk) genomic tumor aberrations. (1.2)", "lazcluze is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 l858r substitution mutations, as detected by an fda-approved test. (1)", "libtayo is a programmed death receptor-1 (pd-1) blocking antibody indicated: cutaneous squamous cell carcinoma (cscc) \u2022 for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mcscc) or locally advanced cscc (lacscc) who are not candidates for curative surgery or curative radiation. (1.1) basal cell carcinoma (bcc) \u2022 for the treatment of patients with locally advanced or metastatic bcc (labcc or mbcc) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. (1.2) non-small cell lung cancer (nsclc) \u2022 in combination with platinum\u2010based chemotherapy for the first\u2010line treatment of adult patients with non-small cell lung cancer (nsclc) with no egfr, alk or ros1 aberrations and is: \u2022 locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or \u2022 metastatic. (1.3) \u2022 as single agent for the first-line treatment of adult patients with nsclc whose tumors have high pd-l1 expression [tumor proportion score (tps) \u2265 50%] as determined by an fda-approved test, with no egfr, alk or ros1 aberrations, and is: \u2022 locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or \u2022 metastatic. (1.3, 2.1) _______________", "herceptin is a her2/neu receptor antagonist indicated in adults for: \u2022 the treatment of her2-overexpressing breast cancer. (1.1, 1.2) \u2022 the treatment of her2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. (1.3) select patients for therapy based on an fda-approved companion diagnostic for herceptin (1, 2.2).", "truqap is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer with one or more pik3ca/akt1/pten-alterations as detected by an fda-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. (1)", "infection, and constipation. the most common laboratory abnormalities \u2022 adult and pediatric patients 1 year of age and older with chronic phase ph+ (\u226520%) in adult and pediatric patients are creatinine increased, hemoglobin chronic myelogenous leukemia (cml), newly-diagnosed or resistant or decreased, lymphocyte count decreased, platelets decreased, alt intolerant to prior therapy. (1) increased, calcium decreased, white blood cell count decreased, ast \u2022 adult patients with accelerated, or blast phase ph+ cml with resistance or increased, absolute neutrophil count decreased, glucose increased, intolerance to prior therapy. (1) phosphorus decreased, urate increased, alkaline phosphatase increased, lipase increased, creatine kinase increased, and amylase increased. (6.1) ----------------------", "perjeta is a her2/neu receptor antagonist indicated for: \u2022 use in combination with trastuzumab and docetaxel for treatment of patients with her2-positive metastatic breast cancer (mbc) who have not received prior anti-her2 therapy or chemotherapy for metastatic disease. (1.1) \u2022 use in combination with trastuzumab and chemotherapy as o neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (1.2, 2.2, 14.2) o adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence (1.2, 2.2, 14.3)", "rezlidhia is an isocitrate dehydrogenase-1 (idh1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (aml) with a susceptible idh1 mutation as detected by an fda-approved test. (1)", "ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: \u2022 an aromatase inhibitor as initial endocrine-based therapy (1); or \u2022 fulvestrant in patients with disease progression following endocrine therapy. (1)", "gilotrif is a kinase inhibitor indicated for: ! first-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have non-resistant epidermal growth factor receptor (egfr) mutations as detected by an fda-approved test (1.1) limitations of use: safety and efficacy of gilotrif were not established in patients whose tumors have resistant egfr mutations (1.1) ! treatment of patients with metastatic, squamous nsclc progressing after platinum-based chemotherapy (1.2)", "enhertu is a her2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: \u2022 adult patients with unresectable or metastatic her2-positive (ihc 3+ or ish positive) breast cancer who have received a prior anti-her2-based regimen either: o in the metastatic setting, or o in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. (1.1) \u2022 adult patients with unresectable or metastatic her2-low (ihc 1+ or ihc 2+/ish-) breast cancer, as determined by an fda-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. (1.2) \u2022 adult patients with unresectable or metastatic non-small cell lung cancer (nsclc) whose tumors have activating her2 (erbb2) mutations, as detected by an fda-approved test, and who have received a prior systemic therapy.* (1.3) \u2022 adult patients with locally advanced or metastatic her2-positive (ihc 3+ or ihc 2+/ish positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. (1.4) \u2022 adult patients with unresectable or metastatic her2-positive (ihc 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.* (1.5) * these indications are approved under accelerated approval based on objective response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. (14.3, 14.5)", "gavreto is a kinase inhibitor indicated for treatment of: \u2022 adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer as detected by an fda approved test (nsclc). (1.1) \u2022 adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). (1.2) _______________", "tasigna is a kinase inhibitor indicated for the treatment of:  adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase. (1.1)  adult patients with chronic phase (cp) and accelerated phase (ap) ph+ cml resistant to or intolerant to prior therapy that included imatinib. (1.2)  pediatric patients greater than or equal to 1 year of age with ph+ cml-cp and cml-ap resistant or intolerant to prior tyrosine-kinase inhibitor (tki) therapy. (1.3)", "tazverik is a methyltransferase inhibitor indicated for the treatment of:  adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. (1.1)  adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. (1.2)  adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. (1.2) these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).", "truseltiq is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test. (1, 2.1) this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). (1)", "itovebi is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, pik3ca-mutated, hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, locally advanced or metastatic breast cancer, as detected by an fda-approved test, following recurrence on or after completing adjuvant endocrine therapy. (1, 14.1)", "verzenio\u00ae is a kinase inhibitor indicated: \u2022 in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node-positive, early breast cancer at high risk of recurrence. (1.1, 14.1) \u2022 in combination with an aromatase inhibitor as initial endocrine- based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. (1.2) \u2022 in combination with fulvestrant for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. (1.2) \u2022 as monotherapy for the treatment of adult patients with hr- positive, her2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. (1.2)", "tafinlar is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test. (1.1, 2.1) tafinlar is indicated, in combination with trametinib, for: \u2022 the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations as detected by an fda-approved test. (1.2, 2.1) \u2022 the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection. (1.3, 2.1) \u2022 the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test. (1.4, 2.1) \u2022 the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options. (1.5, 2.1) \u2022 the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. this indication is approved under accelerated approval based on overall response rate (orr) and duration of response (dor). continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1.6, 2.1) \u2022 the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy. (1.7, 2.1) limitations of use: tafinlar is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibition. (1.8, 12.1) tafinlar is not indicated for treatment of patients with wild- type braf solid tumors. (5.2)", "augtyro is a kinase inhibitor indicated for the treatment of \u2022 adult patients with locally advanced or metastatic ros1-positive non- small cell lung cancer (nsclc). (1.1) \u2022 adult and pediatric patients 12 years of age and older with solid tumors that: \u2022 have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion and \u2022 are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity. \u2022 have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.2)", "erbitux\u00ae is an epidermal growth factor receptor (egfr) antagonist indicated for treatment of: head and neck cancer \u2022 locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. (1.1, 14.1) \u2022 recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum- based therapy with fluorouracil. (1.1, 14.1) \u2022 recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. (1.1, 14.1) colorectal cancer \u2022 k-ras wild-type, egfr-expressing, metastatic colorectal cancer as determined by an fda-approved test o in combination with folfiri for first-line treatment, o in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, o as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. (1.2, 5.7, 12.1, 14.2) limitations of use: erbitux is not indicated for treatment of ras- mutant colorectal cancer or when the results of the ras mutation tests are unknown. (5.7) \u2022 braf v600e mutation-positive metastatic colorectal cancer (crc) o in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy. (1.3)", "balversa is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (muc) with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. select patients for therapy based on an fda-approved companion diagnostic for balversa. (1, 2.1) limitations of use balversa is not recommended for the treatment of patients who are eligible for and have not received prior pd-1 or pd-l1 inhibitor therapy. (1, 14.1)", "braftovi is a kinase inhibitor indicated: melanoma \u2022 in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. (1.1, 2.1) colorectal cancer (crc) \u2022 in combination with cetuximab and mfolfox6, for the treatment of patients with metastatic colorectal cancer (mcrc) with a braf v600e mutation, as detected by an fda-approved test. (1.2, 2.1) this indication is approved under accelerated approval based on response rate and durability of response [see clinical studies (14.2)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). \u2022 in combination with cetuximab, for the treatment of adult patients with metastatic crc with a braf v600e mutation, as detected by an fda-approved test, after prior therapy. (1.2, 2.1) non-small cell lung cancer (nsclc) \u2022 in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with a braf v600e mutation, as detected by an fda-approved test. (1.3, 2.1) limitations of use braftovi is not indicated for treatment of patients with wild-type braf melanoma, wild-type braf crc, or wild-type braf nsclc. (1.4, 5.2)", "mektovi is a kinase inhibitor indicated:  in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda-approved test. (1.1, 2.1)  in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) with a braf v600e mutation, as detected by an fda-approved test. (1.2, 2.1)", "ensacove is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc) who have not previously received an alk-inhibitor. (1, 2.1)", "imfinzi is a programmed death-ligand 1 (pd-l1) blocking antibody indicated:  in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by imfinzi continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (nsclc) and no known epidermal growth factor receptor (egfr) mutations or anaplastic lymphoma kinase (alk) rearrangements. (1.1)  as a single agent, for the treatment of adult patients with unresectable, stage iii nsclc whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (1.1)  in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic nsclc with no sensitizing egfr mutations or alk genomic tumor aberrations. (1.1)  in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc). (1.2)  in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (btc). (1.3)  in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uhcc). (1.4)  in combination with carboplatin and paclitaxel followed by imfinzi as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dmmr). (1.5)", "lytgobi is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (fgfr2) gene fusions or other rearrangements. (1, 2.1) this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (1)", "bizengri\u00ae is a bispecific her2- and her3-directed antibody indicated for the treatment of: \u2022 adults with advanced, unresectable or metastatic non-small cell lung cancer (nsclc) harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy.* (1.1) \u2022 adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (nrg1) gene fusion with disease progression on or after prior systemic therapy.* (1.2) *this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).", "tykerb is a kinase inhibitor indicated in combination with: (1) \u2022 capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (her2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. limitations of use: patients should have disease progression on trastuzumab prior to initiation of treatment with tykerb in combination with capecitabine. \u2022 letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.", "rozlytrek is a kinase inhibitor indicated for the treatment of: \u2022 adult patients with ros1-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test. (1.1) \u2022 adult and pediatric patients older than 1 month of age with solid tumors that: o have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion, as detected by an fda-approved test without a known acquired resistance mutation, o are metastatic or where surgical resection is likely to result in severe morbidity, and o have progressed following treatment or have no satisfactory alternative therapy. this indication is approved under accelerated approval based on tumor response rate and durability of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.2)", "opdivo is a programmed death receptor-1 (pd-1)-blocking antibody indicated for the treatment of: melanoma \u2022 adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) \u2022 for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage iib, stage iic, stage iii, or stage iv melanoma. (1.2) non-small cell lung cancer (nsclc) \u2022 adult patients with resectable (tumors \u22654 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) \u2022 adult patients with resectable (tumors \u22654 cm or node positive) non-small cell lung cancer and no known egfr mutations or alk rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent opdivo as adjuvant treatment after surgery. (1.4) \u2022 adult patients with metastatic non-small cell lung cancer expressing pd-l1 (\u22651%) as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) \u2022 adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) \u2022 adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. patients with egfr or alk genomic tumor aberrations should have disease progression on fda-approved therapy for these aberrations prior to receiving opdivo. (1.5) malignant pleural mesothelioma \u2022 adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) renal cell carcinoma (rcc) \u2022 adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) \u2022 adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) \u2022 adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) classical hodgkin lymphoma (chl) \u2022 adult patients with classical hodgkin lymphoma that has relapsed or progressed aftera: (1.8) \u2022 autologous hematopoietic stem cell transplantation (hsct) and brentuximab vedotin, or \u2022 3 or more lines of systemic therapy that includes autologous hsct. squamous cell carcinoma of the head and neck (scchn) \u2022 adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) urothelial carcinoma \u2022 adjuvant treatment of adult patients with urothelial carcinoma (uc) who are at high risk of recurrence after undergoing radical resection of uc. (1.10) \u2022 adult patients with unresectable or metastatic urothelial carcinoma, as first- line treatment in combination with cisplatin and gemcitabine. (1.10) \u2022 adult patients with locally advanced or metastatic urothelial carcinoma who: \u2022 have disease progression during or following platinum-containing chemotherapy. \u2022 have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) colorectal cancer \u2022 adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) colorectal cancer (crc) in combination with ipilimumab. (1.11) \u2022 adult and pediatric (12 years and older) patients with microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (1.11) hepatocellular carcinoma (hcc) \u2022 adult patients with unresectable or metastatic hepatocellular carcinoma (hcc), as a first-line treatment in combination with ipilimumab. (1.12) \u2022 in combination with ipilimumab in adult patients with unresectable or metastatic hcc who have been previously treated with sorafenib. (1.12) esophageal cancer \u2022 adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (crt). (1.13) \u2022 adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.13) \u2022 adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab. (1.13) \u2022 adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (escc) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma \u2022 adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a this indication is approved under accelerated approval based on overall response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."]